Supernus Pharmaceuticals (SUPN) Tmuɣli n wazal
Supernus Pharmaceuticals
Ṛṛbem n lḥedd$42.66Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-1.50%
Asnulfu n AI: SUPN
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and delivers patented medicines for the treatment of central nervous system disorders and diseases, including clinical-stage candidates for neurological and psychiatric conditions such as epilepsy, conductive disorder, Parkinson’s disease, ADHD and depression.
